News Release

Survival benefit for rheumatoid arthritis patients treated with methotrexate

N.B. Please note the embargo date for this Lancet press material is Friday 5 April 2002

Peer-Reviewed Publication

The Lancet_DELETED

The anticancer drug methotrexate could have a substantial survival benefit among patients with rheumatoid arthritis, conclude authors of a prospective US study in this week’s issue of THE LANCET.

Rheumatoid arthritis is a chronic inflammatory disease which results in reduced life-expectancy and is associated with cardiovascular disease, infection, and cancer. Low-dose methotrexate is the main choice of antirheumatic therapy for rheumatoid arthritis, although its effect on mortality for patients with the disease is not known.

Hyon Choi from Harvard Medical School and Harvard School of Public Health, Frederick Wolfe from University of Kansas School of Medicine, USA, and colleagues prospectively studied 1240 patients with rheumatoid arthritis over the past two decades. 191 individuals died during follow-up. Patients who began treatment with methotrexate (around half of the study population) had more severe rheumatoid arthritis. After adjustment for this confounding factor, methotrexate was found to have a 60% survival benefit for all-cause mortality compared with those who did not use methotrexate, and a 70% survival benefit for cardiovascular death.

Hyon Choi comments: “Our data indicate that methotrexate may provide a substantial survival benefit, largely by reducing cardiovascular mortality. This gain in life expectancy could be considered in selecting a cost-effective, disease-modifying antirheumatic drug on a long-term basis. Additionally, the survival benefit of methotrexate would set a standard against which new disease-modifying antirheumatic drugs should be compared.”

###

Contact: Professor Fredrick Wolfe, National Data Bank for Rheumatic Diseases, Arthritis Research Center Foundation, 1035 N Emporia, Suite 230, Wichita, KS 67214, USA; T) +1 316 263 2125; F) +1 316 263 0761; E) fwolfe@arthritis-research.org


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.